0001437749-20-013673.txt : 20200623
0001437749-20-013673.hdr.sgml : 20200623
20200623164707
ACCESSION NUMBER: 0001437749-20-013673
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200619
FILED AS OF DATE: 20200623
DATE AS OF CHANGE: 20200623
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ferrante Karen Jean
CENTRAL INDEX KEY: 0001598502
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-23143
FILM NUMBER: 20982708
MAIL ADDRESS:
STREET 1: 150 ADIRONDACK DRIVE
CITY: EAST GREENWICH
STATE: RI
ZIP: 02818
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PROGENICS PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000835887
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133379479
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE WORLD TRADE CENTER
STREET 2: 47TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10007
BUSINESS PHONE: 646-975-2500
MAIL ADDRESS:
STREET 1: ONE WORLD TRADE CENTER
STREET 2: 47TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10007
4
1
rdgdoc.xml
FORM 4
X0306
4
2020-06-19
1
0000835887
PROGENICS PHARMACEUTICALS INC
PGNX
0001598502
Ferrante Karen Jean
ONE WORLD TRADE CENTER
47TH FLOOR, SUITE J
NEW YORK
NY
10007
1
Stock Option (Right to Buy)
4.50
2020-06-19
4
D
0
40000
D
2024-01-28
Common Stock
40000
0
D
Stock Option (Right to Buy)
4.47
2020-06-19
4
D
0
20000
D
2024-06-16
Common Stock
20000
0
D
Stock Option (Right to Buy)
6.72
2020-06-19
4
D
0
20000
D
2025-06-09
Common Stock
20000
0
D
Stock Option (Right to Buy)
4.89
2020-06-19
4
D
0
20000
D
2026-06-07
Common Stock
20000
0
D
Stock Option (Right to Buy)
6.95
2020-06-19
4
D
0
20000
D
2027-06-13
Common Stock
20000
0
D
Stock Option (Right to Buy)
8.99
2020-06-19
4
D
0
25000
D
2028-06-12
Common Stock
25000
0
D
Stock Option (Right to Buy)
5.74
2020-06-19
4
D
0
25000
D
2029-07-11
Common Stock
25000
0
D
On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect. Each of these options is fully vested and exercisable.
/s/ Karen Ferrante
2020-06-23